ALKS 4230

Alkermes Plc (NASDAQ: ALKS) revealed Wednesday that it initiated a phase 1 clinical trial of its immuno-oncology drug candidate, ALKS 4230, which was formerly referred to as RDB 1450, a novel Selective Effector Cell Activator protein designed for targeted interleukin-2 (IL-2) receptor activation....